KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.

Carl Regillo, Peter K Kaiser, Peter J Kertes, Mark Gillies, Tina Maio-Twofoot, David Lawrence, Frank G Holz

Eye (Lond) 40(3) 369-375

PMID41413355
PMCIDPMC12881385
DOI10.1038/s41433-025-04161-x
发表日期2025-12-18
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:非 KM 图。
摘要

摘要

OBJECTIVE: To compare the efficacy and safety of brolucizumab 6 mg and aflibercept 2 mg in patients with neovascular age-related macular degeneration (nAMD) using an identical 4-week adjustment Treat-and-Extend regimen. METHODS: Patients received brolucizumab (n = 366) or aflibercept (n = 368) at Weeks 0, 4, 8 and 16, followed by 4-week interval adjustments depending on disease activity (DA) up to a maximum treatment interval of 16 weeks (q16w). After introduction of the urgent safety measure (USM), patients in either arm requiring a 4-week interval were discontinued from study treatment and moved to standard of care (SoC). RESULTS: At Week 64, more brolucizumab patients had a last treatment interval of q16w with no DA vs aflibercept (28.4% vs 12.2%). In the brolucizumab arm, 22.4%, 26.0% and 23.2% of patients were on treatment intervals of 12, 8 and 4 weeks (on SoC after USM), respectively, compared with 23.9%, 22.0% and 41.8% in the aflibercept arm. The average change in best-corrected visual acuity (letters) from baseline at Weeks 60 and 64 was comparable (brolucizumab: +4.7; aflibercept: +4.9). Average change in central subfield thickness (µm) at Weeks 60 and 64 was -182.9 µm in the brolucizumab arm vs -167.5 µm with aflibercept. Incidence of ocular adverse events (AEs), serious ocular AEs and AEs of special interest in the brolucizumab vs aflibercept arms were 31.1% vs 27.7%, 2.7% vs 0.8%, 6.0% vs 1.6%, respectively. CONCLUSIONS: The Week 64 results in TALON reaffirmed those reported at Week 32, demonstrating extended treatment intervals and an overall favourable benefit/risk profile for brolucizumab in patients with nAMD.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1TALON study design. BCVA best-corrected visual acuity, DA disease activity, EOS end of study, EOT end of treatment, nAMD neovascular age-related macular degeneration, q4w every 4 weeks, q8w every 8 weeks, q12w every 12 weeks. At the investigator’s discretion, an inspection visit may have been performed at Week 14, for 8-week treatment interval. If the treatment interval is extended from 8 to 12 weeks, an optional assessment can be performed 10 weeks after the last treatment visit. *The treatment interval could also be maintained if the investigator deemed that the patient would not benefit from injection interval extension. # Week 62, depending on visit schedule.
非 KM Figure
Fig. 2Proportion of patients with the last interval with no DA* (n/N %) at Week 64. Pre-specified secondary endpoint. DA disease activity, n the number of participants at 4-/8-/12-/16-week intervals as the last interval with no DA, N the number of participants in the full analysis set per treatment arm, q4w every 4 weeks, q8w every 8 weeks, q12w every 12 weeks, q16w every 16 weeks. DA is as assessed by an investigator. If the duration of the last interval falls within the following ranges of (q4w, q8w) or (q8w, q12w) or (q12w, q16w) or ≥q16w, then the floor value of these ranges i.e. q4w, q8w, or q12w, q16w, respectively, are used for imputation.
非 KM Figure
Fig. 3Mean change in BCVA from baseline to Week 64. Pre-specified secondary endpoint. AFL aflibercept, ANOVA Analysis of variance, BCVA best-corrected visual acuity, BRO brolucizumab, CI confidence interval, LOCF Last Observation Carried Forward, LS least squares, SE standard error. LOCF. ANOVA model with treatment arm (factor), baseline BCVA categories (≤54, 55 to ≤73, ≥74 letters), and age categories (<75 years, ≥75 years) as fixed effects. BCVA values collected after the start of an alternative treatment were replaced by the last value prior to start of alternative treatment. If Week 60 BCVA value is not available, Week 62 BCVA is used; otherwise LOCF is applied. The primary objective was met upon significance of both non-inferiority of average change in BCVA from baseline at Weeks 28 and 32 and superiority of distribution of the last interval without DA up to Week 32.
非 KM Figure
Fig. 4Line plot of mean change in CSFT from baseline by visit up to Week 64. Secondary endpoint. ANOVA Analysis of variance, CI confidence interval, CSFT central subfield thickness, LOCF last observation carried forward, LS least squares, SE standard error. ANOVA baseline CSFT categories (<400 μm, ≥400 μm), age categories (<75 years, ≥75 years) and treatment as fixed effects. If Week 28/60 CSFT value is not available, Week 30/62 CSFT is used, otherwise LOCF is used.
非 KM Figure